- Revenue increased 15.3% to S$9.8 million in 6MFY2020 due to contributions from its new and existing subsidiaries
- Declared a higher interim dividend Y-O-Y at S$0.013 per ordinary share
Catalist-listed HC Surgical Specialists Limited (SGX:1B1) today announced its financial results for the three months ended 30 November 2019 (“2QFY2020”) and half-year ended 30 November 2019 (“6MFY2020”).
Annotating on the Group’s 2QFY2020 and 6MFY2020 results, Chief Executive Officer of HCSS, Dr. Heah Sieu Min said, “We have a steady growth that allows expansion to continue. We have made positive financial and operational progress during the period, including an improved revenue and profit trend. As part of our commitment to enhance shareholders’ value, we have raised our interim dividend by 30% to S$0.013 per ordinary share, which is in line with our improved core operational performance.”
Dr. Heah Sieu Min added, “The Group continues to seize good opportunities to accelerate the company’s strategy which will continue to be reviewed on a regular and disciplined basis – expanding our clinic locations and nurturing the next generation of doctors to provide quality accessible healthcare to your doorstep.”